Clinical Trial Update: LRFN5 and OLFM4 in Bipolar Disorder

View source ↗

Summary

A completed clinical trial evaluating LRFN5 and OLFM4 as biomarkers in Bipolar Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Snippet

Sponsor: Elazığ Mental Health and Diseases Hospital | Conditions: Bipolar Disorder (BD) | Status: COMPLETED